Perrigo (PRGO) Projected to Post Earnings on Thursday

Perrigo (NYSE:PRGO) is expected to be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Perrigo to post earnings of $0.80 per share and revenue of $1.0921 billion for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Perrigo Stock Performance

PRGO opened at $14.61 on Thursday. The stock has a 50-day moving average of $14.23 and a 200-day moving average of $17.92. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.44 and a current ratio of 2.51. Perrigo has a 52-week low of $12.17 and a 52-week high of $30.93. The company has a market cap of $2.01 billion, a PE ratio of -38.43, a price-to-earnings-growth ratio of 1.30 and a beta of 0.39.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on PRGO shares. Argus raised shares of Perrigo to a “hold” rating in a research report on Wednesday, January 14th. Canaccord Genuity Group lowered their target price on shares of Perrigo from $40.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, November 6th. JPMorgan Chase & Co. cut their target price on shares of Perrigo from $20.00 to $18.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Weiss Ratings restated a “sell (d+)” rating on shares of Perrigo in a report on Monday, December 22nd. Finally, Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a research note on Friday, February 13th. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $20.33.

Institutional Investors Weigh In On Perrigo

Hedge funds have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD increased its stake in Perrigo by 3.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 17,574,227 shares of the company’s stock valued at $244,634,000 after acquiring an additional 653,925 shares during the period. Fuller & Thaler Asset Management Inc. grew its holdings in shares of Perrigo by 291.9% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 7,824,759 shares of the company’s stock worth $108,921,000 after purchasing an additional 5,828,076 shares in the last quarter. State Street Corp increased its position in shares of Perrigo by 9.5% during the second quarter. State Street Corp now owns 7,340,323 shares of the company’s stock valued at $196,134,000 after purchasing an additional 637,678 shares during the period. Ion Asset Management Ltd. raised its stake in shares of Perrigo by 34.7% in the second quarter. Ion Asset Management Ltd. now owns 3,817,621 shares of the company’s stock valued at $102,007,000 after purchasing an additional 983,727 shares in the last quarter. Finally, Wellington Management Group LLP lifted its position in Perrigo by 2.5% in the third quarter. Wellington Management Group LLP now owns 2,050,868 shares of the company’s stock worth $45,673,000 after purchasing an additional 49,057 shares during the period. Institutional investors own 95.91% of the company’s stock.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.